Our livers contain many different types of immune cells. New research by the team of Prof. Charlotte Scott (VIB-UGent Center ...
Our livers contain many different types of immune cells. New research by the team of Prof. Charlotte Scott (VIB-UGent Center ...
Vigil Neuroscience advances VG-3927, a small molecule TREM2 agonist, into Phase II Alzheimer’s trials in Q3 2025 following ...
Research from VIB-UGent identifies lipid-associated macrophages and LAM-like Kupffer cells as critical for liver repair. The ...
Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...
Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential ...
Shares of Vigil Neuroscience (NASDAQ:VIGL) rose ~18% in the premarket on Thursday after the Sanofi (SNY)-backed biotech said that it expects to advance its Alzheimer's candidate VG-3927 into a Phase 2 ...
Mizuho Securities analyst Graig Suvannavejh has reiterated their bullish stance on VIGL stock, giving a Buy rating today.Invest with ...
Vigil Neuroscience (VIGL) stock rises as the Sanofi (SNY)-backed biotech plans to advance its Alzheimer's candidate VG-3927 ...
Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report) and keeping the price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback